Does omega-3 supplementation improve dry eye symptoms?
Moderate EvidenceIT DEPENDS
Moderate but conflicting evidence exists for omega-3 supplementation improving dry eye symptoms. Earlier studies and meta-analyses favored benefit, but the large DREAM trial found no advantage over placebo, creating uncertainty about true efficacy.
The Verdict
Moderate but conflicting evidence exists for omega-3 supplementation improving dry eye symptoms. Earlier studies and meta-analyses favored benefit, but the large DREAM trial found no advantage over placebo, creating uncertainty about true efficacy.
What the Evidence Shows
Omega-3 fatty acids (EPA and DHA) have anti-inflammatory properties that theoretically benefit dry eye disease by modulating meibomian gland lipid composition, reducing ocular surface inflammation, and improving tear film stability. Multiple smaller RCTs and meta-analyses published between 2010-2016 reported statistically significant improvements in dry eye symptoms (OSDI scores), tear break-up time, and Schirmer test values with omega-3 supplementation. However, the 2018 DREAM (Dry Eye Assessment and Management) study—the largest and most rigorous trial to date with 535 participants—found no significant difference between omega-3 supplementation (3000mg EPA+DHA daily) and olive oil placebo over 12 months on any primary or secondary outcome. This result challenged prior positive findings and raised questions about publication bias in earlier literature. Subsequent analyses suggest the olive oil placebo in DREAM may have had active anti-inflammatory effects, potentially masking treatment differences. A 2019 Cochrane review concluded that evidence is uncertain, noting moderate-quality evidence of symptom improvement but acknowledging the DREAM trial's null finding. The discrepancy between earlier positive trials and DREAM remains unresolved, with potential explanations including different patient populations, formulations, dosages, and placebo selection.
Evidence Quality
3
Meta-Analyses
12
RCTs
6
Observational
Important Caveats
- ⚠️ The largest trial (DREAM, n=535) found no benefit over olive oil placebo
- ⚠️ Olive oil placebo in DREAM may have had active anti-inflammatory properties
- ⚠️ Earlier positive trials were generally smaller with higher risk of bias
- ⚠️ Optimal EPA:DHA ratio and dosage for ocular benefit remain unclear
- ⚠️ Response may depend on dry eye subtype (evaporative vs. aqueous deficient)
Population Studied
Adults with moderate-to-severe dry eye disease; predominantly women over 40; office workers with computer-related dry eye; post-menopausal women
Dosage
Studies used 1000-3000mg/day of combined EPA and DHA; DREAM trial used 2000mg EPA + 1000mg DHA daily; some trials used re-esterified triglyceride forms
Duration
Treatment durations ranged from 6 weeks to 12 months; the DREAM study assessed outcomes at 6 and 12 months
Supporting Studies (3)
Omega-3 fatty acids for dry eye disease: a meta-analysis of randomized controlled trials
Meta-AnalysisGiannaccare G, Pellegrini M, Sebastiani S, et al. · Cornea (2019)
Meta-analysis of 17 RCTs (3363 patients) found omega-3 supplementation significantly improved OSDI symptom scores (MD -4.94, 95% CI -8.27 to -1.60), tear break-up time, and Schirmer test values compared to placebo.
View paper (DOI) →A randomized controlled trial of omega-3 fatty acids in dry eye syndrome
RCTKangari H, Eftekhari MH, Sardari S, et al. · Nutrition Journal (2013)
In 64 patients with dry eye, omega-3 supplementation (180mg EPA + 120mg DHA twice daily) for 30 days significantly improved tear break-up time, Schirmer scores, and OSDI symptom scores compared to placebo.
View paper (DOI) →Oral omega-3 supplementation and dry eye in contact lens wearers
RCTBhargava R, Kumar P, Phogat H, et al. · Cornea (2015)
Among 496 symptomatic contact lens wearers, 6 months of omega-3 supplementation (EPA 720mg + DHA 480mg daily) significantly reduced dry eye symptoms and improved tear film stability versus placebo.
View paper (DOI) →Contradicting Studies (2)
n-3 fatty acid supplementation for the treatment of dry eye disease (DREAM study)
RCTThe Dry Eye Assessment and Management Study Research Group. · New England Journal of Medicine (2018)
In 535 participants with moderate-to-severe dry eye, 12 months of omega-3 supplementation (3000mg EPA+DHA daily) did not improve OSDI scores, conjunctival staining, tear break-up time, or Schirmer scores compared to olive oil placebo.
Why this disagrees:
As the largest and most methodologically rigorous trial, DREAM's null result carries substantial weight. The olive oil placebo contained oleic acid which has anti-inflammatory properties, potentially acting as an active comparator rather than true placebo. This may have narrowed the treatment difference.
Omega-3 supplementation and dry eye: a Cochrane systematic review
Meta-AnalysisDownie LE, Ng SM, Lindsley KB, Akpek EK. · Cochrane Database of Systematic Reviews (2019)
Cochrane review found uncertain evidence that omega-3 supplements reduce dry eye symptoms, noting that while some trials show benefit, the large DREAM trial's null result and moderate risk of bias across studies preclude definitive conclusions.
Why this disagrees:
The Cochrane analysis weighted the DREAM study heavily due to its superior methodology, large sample size, and low risk of bias, concluding that certainty of evidence was low to moderate and insufficient to recommend routine omega-3 supplementation for dry eye.